JPMorgan Chase & Co. raised its holdings in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 80.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,124 shares of the biopharmaceutical company’s stock after acquiring an additional 50,378 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.11% of Juno Therapeutics worth $3,382,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Pacad Investment Ltd. purchased a new position in Juno Therapeutics during the 2nd quarter valued at about $105,000. Great West Life Assurance Co. Can increased its holdings in Juno Therapeutics by 80.5% during the 1st quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 3,800 shares in the last quarter. Brighton Jones LLC purchased a new position in Juno Therapeutics during the 2nd quarter valued at about $260,000. CAPROCK Group Inc. purchased a new position in Juno Therapeutics during the 2nd quarter valued at about $299,000. Finally, Utah Retirement Systems increased its holdings in Juno Therapeutics by 1.8% during the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 67.38% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Acquires 50,378 Shares of Juno Therapeutics, Inc. (JUNO)” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://transcriptdaily.com/2017/10/11/jpmorgan-chase-co-acquires-50378-shares-of-juno-therapeutics-inc-juno.html.
Several research firms have weighed in on JUNO. Zacks Investment Research downgraded shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Morgan Stanley raised their target price on shares of Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a report on Monday, August 7th. Vetr downgraded shares of Juno Therapeutics from a “buy” rating to a “hold” rating and set a $28.85 target price for the company. in a report on Monday, June 26th. BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 20th. Finally, ValuEngine upgraded shares of Juno Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Juno Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $37.83.
In other Juno Therapeutics news, EVP Robert Azelby sold 12,850 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $44.95, for a total transaction of $577,607.50. Following the completion of the sale, the executive vice president now directly owns 37,439 shares of the company’s stock, valued at $1,682,883.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Insiders have sold 8,085,004 shares of company stock valued at $219,551,561 over the last ninety days. Insiders own 15.26% of the company’s stock.
Shares of Juno Therapeutics, Inc. (NASDAQ JUNO) opened at 43.19 on Wednesday. The stock’s 50 day moving average is $41.59 and its 200-day moving average is $29.86. The stock’s market capitalization is $4.53 billion. Juno Therapeutics, Inc. has a one year low of $17.52 and a one year high of $47.03.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. During the same period in the prior year, the company posted ($0.64) earnings per share. Juno Therapeutics’s quarterly revenue was down 22.8% compared to the same quarter last year. On average, equities research analysts expect that Juno Therapeutics, Inc. will post ($3.12) EPS for the current year.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.